434P CodeBreaK 101 subprotocol H: Phase Ib study evaluating combination of sotorasib (Soto), a KRASG12C inhibitor, and panitumumab (PMab), an EGFR inhibitor, in advanced KRAS p.G12C-mutated colorectal cancer (CRC)
Publication
, Conference
Fakih, M; Falchook, GS; Hong, DS; Yaeger, RD; Chan, E; Mather, O; Cardona, P; Dai, T; Strickler, J
Published in: Annals of Oncology
September 2021
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
September 2021
Volume
32
Start / End Page
S551 / S551
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Fakih, M., Falchook, G. S., Hong, D. S., Yaeger, R. D., Chan, E., Mather, O., … Strickler, J. (2021). 434P CodeBreaK 101 subprotocol H: Phase Ib study evaluating combination of sotorasib (Soto), a KRASG12C inhibitor, and panitumumab (PMab), an EGFR inhibitor, in advanced KRAS p.G12C-mutated colorectal cancer (CRC). In Annals of Oncology (Vol. 32, pp. S551–S551). Elsevier BV. https://doi.org/10.1016/j.annonc.2021.08.955
Fakih, M., G. S. Falchook, D. S. Hong, R. D. Yaeger, E. Chan, O. Mather, P. Cardona, T. Dai, and J. Strickler. “434P CodeBreaK 101 subprotocol H: Phase Ib study evaluating combination of sotorasib (Soto), a KRASG12C inhibitor, and panitumumab (PMab), an EGFR inhibitor, in advanced KRAS p.G12C-mutated colorectal cancer (CRC).” In Annals of Oncology, 32:S551–S551. Elsevier BV, 2021. https://doi.org/10.1016/j.annonc.2021.08.955.
Fakih M, Falchook GS, Hong DS, Yaeger RD, Chan E, Mather O, et al. 434P CodeBreaK 101 subprotocol H: Phase Ib study evaluating combination of sotorasib (Soto), a KRASG12C inhibitor, and panitumumab (PMab), an EGFR inhibitor, in advanced KRAS p.G12C-mutated colorectal cancer (CRC). In: Annals of Oncology. Elsevier BV; 2021. p. S551–S551.
Fakih, M., et al. “434P CodeBreaK 101 subprotocol H: Phase Ib study evaluating combination of sotorasib (Soto), a KRASG12C inhibitor, and panitumumab (PMab), an EGFR inhibitor, in advanced KRAS p.G12C-mutated colorectal cancer (CRC).” Annals of Oncology, vol. 32, Elsevier BV, 2021, pp. S551–S551. Crossref, doi:10.1016/j.annonc.2021.08.955.
Fakih M, Falchook GS, Hong DS, Yaeger RD, Chan E, Mather O, Cardona P, Dai T, Strickler J. 434P CodeBreaK 101 subprotocol H: Phase Ib study evaluating combination of sotorasib (Soto), a KRASG12C inhibitor, and panitumumab (PMab), an EGFR inhibitor, in advanced KRAS p.G12C-mutated colorectal cancer (CRC). Annals of Oncology. Elsevier BV; 2021. p. S551–S551.
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
September 2021
Volume
32
Start / End Page
S551 / S551
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis